Gilead Sciences (NASDAQ:GILD) Sets New 52-Week Low at $72.86

Shares of Gilead Sciences, Inc. (NASDAQ:GILDGet Free Report) hit a new 52-week low during mid-day trading on Friday . The company traded as low as $72.86 and last traded at $72.95, with a volume of 5667885 shares. The stock had previously closed at $73.80.

Analyst Upgrades and Downgrades

GILD has been the subject of several research analyst reports. Royal Bank of Canada reduced their price target on shares of Gilead Sciences from $78.00 to $76.00 and set a “sector perform” rating for the company in a research report on Wednesday. Wells Fargo & Company dropped their price target on shares of Gilead Sciences from $90.00 to $84.00 and set an “equal weight” rating for the company in a research note on Wednesday. Cantor Fitzgerald dropped their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research note on Wednesday. Deutsche Bank Aktiengesellschaft started coverage on shares of Gilead Sciences in a research report on Thursday, November 9th. They set a “hold” rating and a $75.00 price objective for the company. Finally, UBS Group lowered their price objective on shares of Gilead Sciences from $85.00 to $84.00 and set a “neutral” rating for the company in a research report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $86.38.

Check Out Our Latest Research Report on Gilead Sciences

Gilead Sciences Trading Down 0.2 %

The company has a debt-to-equity ratio of 1.08, a current ratio of 1.46 and a quick ratio of 1.20. The company has a market cap of $91.80 billion, a price-to-earnings ratio of 16.37, a PEG ratio of 0.96 and a beta of 0.20. The business’s 50-day simple moving average is $80.74 and its 200-day simple moving average is $78.20.

Gilead Sciences (NASDAQ:GILDGet Free Report) last posted its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The firm had revenue of $7.12 billion during the quarter, compared to analyst estimates of $7.10 billion. During the same period in the prior year, the firm earned $1.67 EPS. The business’s quarterly revenue was down 3.7% on a year-over-year basis. Research analysts predict that Gilead Sciences, Inc. will post 7.07 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Thursday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a dividend yield of 4.18%. Gilead Sciences’s dividend payout ratio is 66.67%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 8,242 shares of the stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $85.23, for a total transaction of $702,465.66. Following the sale, the insider now directly owns 82,729 shares of the company’s stock, valued at $7,050,992.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Johanna Mercier sold 8,242 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $85.23, for a total value of $702,465.66. Following the transaction, the insider now owns 82,729 shares of the company’s stock, valued at approximately $7,050,992.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $85.78, for a total transaction of $428,900.00. Following the completion of the transaction, the chief financial officer now directly owns 101,534 shares in the company, valued at $8,709,586.52. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Institutional Trading of Gilead Sciences

Institutional investors and hedge funds have recently modified their holdings of the company. The Manufacturers Life Insurance Company increased its position in Gilead Sciences by 1.4% during the second quarter. The Manufacturers Life Insurance Company now owns 4,188,890 shares of the biopharmaceutical company’s stock worth $322,838,000 after acquiring an additional 56,363 shares during the period. Commonwealth Equity Services LLC increased its stake in Gilead Sciences by 1.5% during the 2nd quarter. Commonwealth Equity Services LLC now owns 346,600 shares of the biopharmaceutical company’s stock worth $26,713,000 after purchasing an additional 5,266 shares in the last quarter. Abundance Wealth Counselors bought a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $1,881,000. Savant Capital LLC grew its stake in shares of Gilead Sciences by 1.3% during the 2nd quarter. Savant Capital LLC now owns 26,776 shares of the biopharmaceutical company’s stock worth $2,064,000 after acquiring an additional 356 shares in the last quarter. Finally, Itau Unibanco Holding S.A. boosted its holdings in shares of Gilead Sciences by 50.6% in the 2nd quarter. Itau Unibanco Holding S.A. now owns 3,713 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 1,247 shares during the last quarter. 82.33% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

(Get Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.

Read More

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.